Clinical Trials and Research

Transthyretin cardiac amyloidosis (ATTR-CM) is an increasingly recognized cause of heart failure and conduction disease in older adults. Resulting from either…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal condition driven by misfolded transthyretin (TTR) protein deposits in the heart muscle…

Details and patient eligibilityAboutThis study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in…

INTRODUCTIONAcquired transthyretin amyloidosis (ATTR) represents a rare but recognized complication in recipients of domino liver transplants (DLT) from donors…

The cross-border transfer of machine learning models based on the International Classification of Diseases, 10th revision (ICD-10) for the identification of rare…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) causes heart failure with substantial morbidity, mortality, and healthcare utilization. ATTRibute-…

AbstractWild-type transthyretin amyloid (ATTRwt) amyloidosis is a systemic, progressive disease that often affects older adults and is characterized by ATTRwt…

Cardiac amyloidosis is an increasingly recognized infiltrative cardiomyopathy characterized by extracellular deposition of misfolded amyloid fibrils within the…

AbstractAims: Eplontersen is an antisense oligonucleotide that suppresses hepatic production of circulating transthyretin (TTR) by targeting TTR mRNA. We present…

BACKGROUND: Acoramidis, an oral transthyretin stabilizer that achieves near-complete (≥90%) transthyretin stabilization, demonstrated significant clinical benefit…